Dose-dependent increase in plasma interleukin-6 after recombinant tumour necrosis factor infusion in humans

N. Sheron, J. N. Lau, J. Hofmann, R. Williams*, G. J.M. Alexander

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

Several studies have shown that the cytokine interleukin-6 (IL-6) is produced in response to tumour necrosis factor (TNF) in vitro. This study examines the in vivo relation between these two cytokines with assays of plasma IL-6 and TNF levels in subjects with chronic hepatitis B undergoing immunomodulatory therapy with recombinant TNF (rTNF). Plasma IL-6 was detected from 20 min after rTNF infusion with levels peaking after 2-3 h and levels correlated with the dose of rTNF administered (r = 0.67, P = 0.004). Peak levels of IL-6 (mean 295, range 266-297 ng/l) were lower than those seen in certain disease states despite the very high peak levels of rTNF (mean 11750, range 5623-18620 ng/l). These findings suggest that the very high levels of IL-6 found in certain disease states are not purely the result of circulating TNF. Other factors such as endotoxin or other cytokines may also play a role in determining levels of plasma IL-6.

Original languageEnglish
Pages (from-to)427-428
Number of pages2
JournalClinical and Experimental Immunology
Volume82
Issue number3
DOIs
Publication statusPublished - 1990
Externally publishedYes

Keywords

  • Chronic hepatitis B
  • Interleukin-6
  • Tumour necrosis factor

Fingerprint

Dive into the research topics of 'Dose-dependent increase in plasma interleukin-6 after recombinant tumour necrosis factor infusion in humans'. Together they form a unique fingerprint.

Cite this